Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1810 results
November 2017
-
Key Release
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-… -
Story Patient Perspectives
Conversations with Patient Advocates: Ron Hollander, president of INCA
Ron Hollander, president of the International Neuroendocrine Cancer Alliance, talks to us about patient advocacy.
-
Media Release
Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
MONALEESA-7 met primary endpoint of progression-free survival, demonstrating superior efficacy of Kisqali combination therapy vs. endocrine treatment alone in first-line treatment of premenopausal… -
Media Release
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1] PsA can lead to reduced… -
Media Release
Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years
For the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Cosentyx® have no radiographic progression of the spine at 4 years[1] These new data… -
Media Release
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Application follows sBLA submission to the FDA for r/r DLBCL which marked second US application for first-ever FDA approved CAR-T therapy Building on the US r/r B-cell ALL experience, Novartis… -
Story Patient Perspectives
Targeting the roots of Sjögren’s syndrome
Early clinical trial reports results in this hidden disease
-
Media Release
Novartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program
Parties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD) Clinical trial is part of the… -
Media Release
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
Primary results of pivotal KymriahTM Phase II JULIET study in relapsed/refractory DLBCL Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to… -
Story Discovery
Exploring longstanding questions about heart disease
New Global Head of Cardiovascular and Metabolic Diseases Research looks to apply new tools to address tough challenges
October 2017
-
Media Release
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
Submission based on updated analyses from global, multi-center Phase II JULIET study, which met primary endpoint, including 6-month data to be presented at ASH 2017 Kymriah has demonstrated… -
Media Release
Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA
Long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting[1],[2] Structural disease progression is a…